Charles River Laboratories International (CRL) Depreciation & Amortization (CF) (2009 - 2025)

Charles River Laboratories International's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $78.3 million for Q4 2025.

• In Q4 2025, Depreciation & Amortization (CF) fell 23.34% year-over-year to $78.3 million; the TTM figure through Dec 2025 stood at $403.3 million (up 11.49% YoY), while the FY2025 annual figure was $403.3 million, up 11.49% from the prior year.
• Depreciation & Amortization (CF) for Q4 2025 stood at $78.3 million, down from $85.2 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $120.4 million in Q1 2025, with the low at $61.5 million in Q1 2021.
• The 5-year median for Depreciation & Amortization (CF) is $78.0 million (2023), against an average of $82.4 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 41.01% in 2025, while the deepest fall reached 23.34% in 2025.
• Charles River Laboratories International's Depreciation & Amortization (CF) stood at $67.2 million in 2021, then climbed by 15.32% to $77.5 million in 2022, then climbed by 3.83% to $80.5 million in 2023, then climbed by 26.82% to $102.1 million in 2024, then decreased by 23.34% to $78.3 million in 2025.
• Business Quant data shows CRL's Depreciation & Amortization (CF) at $78.3 million in Q4 2025, $85.2 million in Q3 2025, and $119.5 million in Q2 2025.